Skip to main content

Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 27, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 26, 2024 -- For older adults with type 2 diabetes, the risk for dementia seems similar with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) dulaglutide, according to a study published online Aug. 27 in the Annals of Internal Medicine.

Bin Hong, from the School of Pharmacy at Sungkyunkwan University in Suwon, South Korea, and colleagues compared the risk for dementia between SGLT2 inhibitors and dulaglutide in a target trial emulation study using nationwide health care data for South Korea obtained between 2010 and 2022. Participants were aged 60 years or older with type 2 diabetes and were initiating treatment with SGLT2 inhibitors (12,489 patients; 51.9 percent dapagliflozin and 48.1 percent empagliflozin) or dulaglutide (1,075 patients).

The researchers found that during a median follow-up of 4.4 years, the primary outcome event of presumed clinical onset of dementia occurred in 69 and 43 participants in the SGLT2 and dulaglutide groups, respectively, with an estimated risk difference of −0.91 percentage points (95 percent confidence interval, −2.45 to 0.63) and estimated risk ratio of 0.81 (95 percent confidence interval, 0.56 to 1.16).

"In conclusion, we found little difference in the risk for dementia for SGLT2 inhibitors compared with dulaglutide in our data," the authors write. "However, whether these findings generalize to newer GLP-1 RAs is uncertain."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2024

Read this next

Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million

FRIDAY, Oct. 18, 2024 -- Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial sizes, according to a research...

Gut Flora Differs in Patients With Epilepsy and Cognitive Dysfunction

WEDNESDAY, Oct. 16, 2024 -- There is an imbalance in the gut flora of patients with epilepsy compared with healthy controls, according to a study published online Sept. 28 in...

Wayfinding Task on Smartphone Can Detect Subjective Cognitive Decline

TUESDAY, Oct. 15, 2024 -- Subtle cognitive changes in patients with subjective cognitive decline can be identified using smartphone data collected during a wayfinding task...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.